Elisabet E. Manasanch
- Hematology top 1%
- Multiple Myeloma Research and Treatments 90
- Oncology top 5%
- Peptidase Inhibition and Analysis 17
- Cancer Treatment and Pharmacology 17
- CAR-T cell therapy research 9
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 14
- Molecular Biology top 10%
- Protein Degradation and Inhibitors 38
- Ubiquitin and proteasome pathways 9
- Amyloidosis: Diagnosis, Treatment, Outcomes 9
- Co-authors
- Robert Z. OrlowskiJulia WilkersonTito FojoMauricio BurottoOla LandgrenSheeba K. ThomasNeha KordeKrina K. Patel
- Cited by
- HematologyOncologyGenetics
- Partner nations
- United StatesSpainSouth Korea
In The Last Decade
Elisabet E. Manasanch
101 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Hematology 721
- Oncology 717
- Genetics 184
- Molecular Biology 1.2k
- Cancer Research 126
Countries citing papers authored by Elisabet E. Manasanch
This map shows the geographic impact of Elisabet E. Manasanch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabet E. Manasanch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabet E. Manasanch more than expected).
Fields of papers citing papers by Elisabet E. Manasanch
This network shows the impact of papers produced by Elisabet E. Manasanch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabet E. Manasanch. The network helps show where Elisabet E. Manasanch may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Elisabet E. Manasanch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2023 | 8 | |
| 3 | 2023 | 1 | |
| 4 | 2022 | 2 | |
| 5 | 2020 | 9 | |
| 6 | 2020 | 5 | |
| 7 | 2020 | 2 | |
| 8 | 2019 | 19 | |
| 9 | 2017 | 1 | |
| 10 | 2017 | 12 | |
| 11 | 2017 | 13 | |
| 12 | 2017 | 11 | |
| 13 | 2017 | 3 | |
| 14 | 2017 | 9 | |
| 15 | Proteasome inhibitors in cancer therapybreakdown → | 2017 | 699 |
| 16 | 2015 | 3 | |
| 17 | 2014 | 15 | |
| 18 | 2014 | 17 | |
| 19 | 2013 | 28 | |
| 20 | 2013 | 6 |
About Elisabet E. Manasanch
Elisabet E. Manasanch is a scholar working on Hematology, Genetics and Oncology, having authored 108 papers that have together received 1.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (90 papers), Protein Degradation and Inhibitors (38 papers), Peptidase Inhibition and Analysis (17 papers), Cancer Treatment and Pharmacology (17 papers), Chronic Lymphocytic Leukemia Research (14 papers), Ubiquitin and proteasome pathways (9 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers) and CAR-T cell therapy research (9 papers). The work is most often cited by research in Hematology (721 citations), Oncology (717 citations) and Genetics (184 citations). Elisabet E. Manasanch has collaborated with scholars based in United States, Spain and South Korea. Frequent co-authors include Robert Z. Orlowski, Julia Wilkerson, Tito Fojo, Mauricio Burotto, Ola Landgren, Sheeba K. Thomas, Neha Korde, Krina K. Patel, Hans C. Lee and Donna M. Weber.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.